Raymond James Financial reissued an outperform rating and acquired a new position in Boston Scientific shares.
1 report, 1 independent
Updated Aug 26
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Raymond James Financial reissued an outperform rating and acquired a new position in Boston Scientific shares.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Raymond James Financial
American Investment Bank and Financial Services Firm
-
Boston Scientific
worldwide developer, manufacturer and marketer of medical devices
Nothing else this week.
-
MarketBeat
American personal finance blog
Related events
- Raymond James Financial reaffirmed a strong-buy rating and Morgan Stanley set a $25.00 price objective for VIR Biotechnology.
- Analyst rating updates for Krystal Biotech, including a buy rating from TD Cowen and a consensus rating from MarketBeat.
- Analyst coverage for Septerna, including a new outperform rating from Raymond James Financial and coverage assumption by Truist Financial, reported via MarketBeat.
- Financial firms Raymond James, CITIC Securities, and Amundi issued rating updates and target price changes for Apple Inc. stock.
- Svi stock was downgraded and its price target lowered by Royal Bank of Canada and Raymond James Financial.